<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04609631</url>
  </required_header>
  <id_info>
    <org_study_id>2019YFC1710302</org_study_id>
    <nct_id>NCT04609631</nct_id>
  </id_info>
  <brief_title>Tai Chi for Comorbid Depression in T2DM Patients</brief_title>
  <official_title>Tai Chi for Comorbid Depression in T2DM Patients: A Randomized Controlled Trial Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chengdu University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Electronic Science and Technology of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chengdu University of Traditional Chinese Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies suggested that Tai Chi may be beneficial for T2DM patients. However, no&#xD;
      studies have investigated the effectiveness of Tai Chi for comorbid depression in T2DM&#xD;
      patients, as well as the optimal frequency of Tai Chi. Thus, we intend to investigate the&#xD;
      effectiveness of Tai Chi for comorbid depression in T2DM patients and test whether the&#xD;
      effectiveness of Tai Chi depends on its frequency.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery Asberg depression rating scale</measure>
    <time_frame>change from baseline to 12 weeks after intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Montgomery Asberg depression rating scale</measure>
    <time_frame>baseline, after intervention (12 weeks), after follow-up (24 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Scale (HAMD) (24-item-version)</measure>
    <time_frame>change from baseline, after intervention (12 weeks), after follow-up (24 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Disability Screening Schedule</measure>
    <time_frame>baseline, after intervention (12 weeks), after follow-up (24 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol-5D questionnaire</measure>
    <time_frame>baseline, after intervention (12 weeks), after follow-up (24 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression scale</measure>
    <time_frame>after intervention (12 weeks), after follow-up (24 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical indicators</measure>
    <time_frame>baseline, after intervention (12 weeks), after follow-up (24 weeks)</time_frame>
    <description>HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose</measure>
    <time_frame>baseline, after intervention (12 weeks), after follow-up (24 weeks)</time_frame>
    <description>Biochemical indicators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial plasma glucose</measure>
    <time_frame>baseline, after intervention (12 weeks), after follow-up (24 weeks)</time_frame>
    <description>Biochemical indicators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin level</measure>
    <time_frame>baseline, after intervention (12 weeks), after follow-up (24 weeks)</time_frame>
    <description>Biochemical indicators</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pittsburgh sleep quality index</measure>
    <time_frame>baseline, after intervention (12 weeks), after follow-up (24 weeks)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hamilton Anxiety Rating Scale</measure>
    <time_frame>baseline, after intervention (12 weeks), after follow-up (24 weeks)</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Depression</condition>
  <condition>T2DM</condition>
  <arm_group>
    <arm_group_label>Tai Chi (5 times/week)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 sessions of Tai Chi per week for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tai Chi (3 times/week)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 sessions of Tai Chi per week for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tai Chi (1 time/week)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 session of Tai Chi per week for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cognitive behavior therapy (CBT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 session of CBT per week for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Waiting-list</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will maintain their routine treatment and life style for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Tai Chi</intervention_name>
    <description>24-form Tai Chi will be performed for 12 weeks. Each session contains a warm-up period (10 minutes), a Tai Chi period (40 minutes) and a cool-down period (10 minutes).</description>
    <arm_group_label>Tai Chi (1 time/week)</arm_group_label>
    <arm_group_label>Tai Chi (3 times/week)</arm_group_label>
    <arm_group_label>Tai Chi (5 times/week)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CBT</intervention_name>
    <description>CBT will be performed once a week for 12 weeks. Each session lasts for 1 hour.</description>
    <arm_group_label>cognitive behavior therapy (CBT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants diagnosed with depression by experienced psychiatrist;&#xD;
&#xD;
          -  Participants diagnosed with T2DM by experienced endocrinologist;&#xD;
&#xD;
          -  Participants aged between 18~75 years;&#xD;
&#xD;
          -  Participants with HbA1c ranges from 6.5% to 8.5%;&#xD;
&#xD;
          -  Participants with Hamilton Depression Scale (HAMD) (24-item-version) ranges from 20~35&#xD;
             scores;&#xD;
&#xD;
          -  Participants passed the Physical Activity Readiness Questionnaire (PAR-Q);&#xD;
&#xD;
          -  Participants willing to complete 12-week intervention and 12-week follow-up.&#xD;
&#xD;
          -  Participants willing to sign informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with uncontrolled hypertension (SBP &gt;160mmHg or DBP &gt;100mmHg after taking&#xD;
             hypotensive drugs);&#xD;
&#xD;
          -  Participants with severe diabetic complications;&#xD;
&#xD;
          -  Regular exercisers (at least 20 minutes/time, 3 times/week) in the last 3 months;&#xD;
&#xD;
          -  Participants with cognitive impairment (Montreal Cognitive Assessment [MoCA] scores&#xD;
             &lt;26);&#xD;
&#xD;
          -  Participants with history of bipolar disorder or schizophrenia or other mental&#xD;
             illness;&#xD;
&#xD;
          -  Participants with contraindications to exercise;&#xD;
&#xD;
          -  Participants with acute, infectious diseases, cancer, or serious neurological disease,&#xD;
             cardiovascular disease, pulmonary disease or other serious medical conditions limiting&#xD;
             the ability;&#xD;
&#xD;
          -  Participants taking psychoactive drugs;&#xD;
&#xD;
          -  Participants participating in other clinical trials at the same time.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Youping Liu, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Chengdu University of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heilongjiang University of Chinese Medicine</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan University of Chinese Medicine</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450046</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Chengdu University of Traditional Chinese Medicine (Sichuan Provincial Hospital of Traditional Chinese Medicine)</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610075</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chengdu University of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Di Qin</investigator_full_name>
    <investigator_title>Chengdu University of Traditional Chinese Medicine</investigator_title>
  </responsible_party>
  <keyword>Tai Chi</keyword>
  <keyword>Depression</keyword>
  <keyword>T2DM</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

